Drug Profile
Research programme: small molecule HER-2 inhibitors - Cengent Therapeutics
Latest Information Update: 31 Aug 2007
Price :
$50
*
At a glance
- Originator Cengent Therapeutics
- Class Small molecules
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 31 Aug 2007 No development reported - Preclinical for Breast cancer in USA (unspecified route)
- 01 Jul 2004 Compounds from this research programme are available for licensing (http://www.cengent.com)
- 23 May 2003 GeneFormatics has merged with Structural Bioinformatics to form Cengent Therapeutics